Imbalance between platelet vascular endothelial growth factor and platelet-derived growth factor in pulmonary hypertension. Effect of prostacyclin therapy
Autor: | Said Sediame, Serge Adnot, Christos Chouaid, Olivier Sitbon, Marc Humbert, Dominique Rideau, Emmanuel Teiger, Gérald Simonneau, Saadia Eddahibi, Bernard Maitre, Chohreh Partovian |
---|---|
Přispěvatelé: | Laboratoire d'étude des textures et application aux matériaux (LETAM), Université Paul Verlaine - Metz (UPVM)-Centre National de la Recherche Scientifique (CNRS), Epidémiologie des maladies infectieuses et modélisation (ESIM), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Laue-Langevin (ILL), ILL, Eddahibi S, M Humbert, S Adnot, S Sediame, C Chouaid, C Partovian, B Maître, E Teiger, Rideau D, Simonneau G, Sitbon O |
Rok vydání: | 2000 |
Předmět: |
Lung Diseases
Male Vascular Endothelial Growth Factor A Platelet-derived growth factor medicine.medical_treatment Prostacyclin Endothelial Growth Factors Critical Care and Intensive Care Medicine MESH: Vascular Endothelial Growth Factors chemistry.chemical_compound MESH: Lung Diseases MESH: Endothelial Growth Factors Platelet Infusions Intravenous MESH: Blood Platelets MESH: Aged Platelet-Derived Growth Factor Lymphokines MESH: Middle Aged biology Vascular Endothelial Growth Factors MESH: Platelet-Derived Growth Factor Middle Aged Endothelial stem cell Vascular endothelial growth factor Female Platelet-derived growth factor receptor medicine.drug Pulmonary and Respiratory Medicine Adult Blood Platelets medicine.medical_specialty Adolescent Hypertension Pulmonary MESH: Epoprostenol Internal medicine MESH: Lung Diseases Obstructive medicine Humans Lung Diseases Obstructive MESH: Infusions Intravenous Aged MESH: Adolescent MESH: Lymphokines MESH: Humans MESH: Hypertension Pulmonary business.industry Growth factor MESH: Vascular Endothelial Growth Factor A MESH: Adult medicine.disease Pulmonary hypertension Epoprostenol MESH: Male Endocrinology chemistry biology.protein [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie business MESH: Female |
Zdroj: | American Journal of Respiratory and Critical Care Medicine American Journal of Respiratory and Critical Care Medicine, American Thoracic Society, 2000, 162 (4 Pt 1), pp.1493-9 American Journal of Respiratory and Critical Care Medicine, 2000, 162 (4 Pt 1), pp.1493-9. ⟨10.1164/ajrccm.162.4.2003124⟩ American Journal of Respiratory and Critical Care Medicine, American Thoracic Society, 2000, 162 (4 Pt 1), pp.1493-9. ⟨10.1164/ajrccm.162.4.2003124⟩ |
ISSN: | 1073-449X 1535-4970 |
Popis: | International audience; Focal vascular injury and impaired endothelial function are features of pulmonary hypertension (PH) that lead to enhanced platelet endothelial cell interactions. Vascular endothelial growth factor (VEGF) is contained in platelets and released at sites of vascular injury to promote endothelial repair and wound healing in combination with platelet-derived nonspecific mitogens such as platelet-derived growth factor (PDGF). The overall balance between platelet VEGF and PDGF was investigated in 21 patients with primary PH, 8 with secondary PH, and 27 with chronic hypoxemic lung disease (CHLD), as well as in 29 control subjects. Platelet VEGF content was increased in patients with primary and secondary PH as compared with control subjects (518 +/- 89, 675 +/- 156, and 166 +/- 29 fg/10(5) platelets, respectively; p < 0.01), whereas platelet PDGF content was similar in the three groups (31 +/- 2, 36 +/- 4, and 33 +/- 3 pg/10(5) platelets, respectively; NS). Patients treated with a continuous prostacyclin infusion had a higher platelet VEGF but a similar platelet PDGF content as compared with untreated patients. Moderate increases in platelet VEGF and PDGF contents were observed in the CHLD patients. We conclude that patients with primary or secondary PH have an increase in platelet VEGF content, but not in platelet PDGF content, and that their platelet VEGF content increases further in response to prostacyclin infusion. We suggest that imbalance between platelet VEGF and PDGF is beneficial to patients with PH. |
Databáze: | OpenAIRE |
Externí odkaz: |